Similarly, OmAd-CM treatment significantly increased immunoreactivity to Ki67 in the GC tumour tissues, but CXCL2 silencing of OmAd significantly suppressed the ability of OmAd to increase Ki67 staining (Fig. 4e, f). Here, CXCL2 is linked to neoplasm.